Urapidil hydrochloride crystal form and preparation method thereof

A technology of urapidil hydrochloride and crystal form, which is applied in the field of medicine and can solve problems such as the preparation of urapidil hydrochloride crystal form.
CN111116491APending Publication Date: 2020-05-08LUOXIN PHARM SHANGHAI CO LTD +1
0 Cites 2 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
LUOXIN PHARM SHANGHAI CO LTD
Publication Date
2020-05-08

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to an urapidil hydrochloride crystal form and a preparation method thereof, specifically to an urapidil hydrochloride crystal form, wherein the X-ray powder diffraction pattern measured by using Cu-Kalpha shows that the crystal form has characteristic diffraction peaks at the following 2[theta] angles: 9.115+ / -0.2 DEG, 15.708+ / -0.2 DEG, 16.203+ / -0.2 DEG, 17.899+ / -0.2 DEG, 18.331+ / -0.2 DEG, 18.904+ / -0.2 DEG, 22.100+ / -0.2 DEG, and 24.294+ / -0.2 DEG.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of medicine, and in particular relates to a crystal form of urapidil hydrochloride and a preparation method thereof. Background technique

[0002] Urapidil hydrochloride (urapidil hydrochloride, chemical name 6-[[3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyl-2 ,4(1H,3H)pyrimidinedione hydrochloride) is a compound having the following chemical structure:

[0003]

[0004] The compound has both peripheral and central hypotensive effects. Peripheral mainly blocks the post-synaptic α1 receptors, causing vasodilation to significantly reduce peripheral resistance. At the same time, it also has a weak presynaptic α2 blocking effect, blocking the vasoconstrictive effect of catecholamines; the central effect is mainly through stimulating the 5-hydroxytryptamine-1A (5-HT1a) receptor, reducing the sympathetic feedback regulation of the medullary cardiovascular center. pressure.

[0005] Clinica...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More